Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
| Autor: | Olga Anagnostou, Evangelia Koutli, Sofia Vasileiadi, Spilios Manolakopoulos, Hariklia Kranidioti, Paris Pantsas, Kanellos Rafail Koustenis, Pinelopi Antonakaki, Melanie Deutsch |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Hepatitis C virus media_common.quotation_subject Psychological intervention people who inject drugs medicine.disease_cause Logistic regression Direct-acting antivirals 03 medical and health sciences 0302 clinical medicine Chronic hepatitis medicine 030212 general & internal medicine Lost to follow-up lost to follow up media_common Response rate (survey) business.industry Addiction Gastroenterology 030211 gastroenterology & hepatology Original Article hepatitis C virus infection sustained virological response business Direct acting |
| Zdroj: | Annals of Gastroenterology |
| ISSN: | 1792-7463 1108-7471 |
| Popis: | Background Direct-acting antivirals (DAAs) offer high cure rates in people who inject drugs (PWID) with hepatitis C virus (HCV) infection. There are concerns regarding lower response rates among PWID in real life. We evaluated the outcome of DAA therapy in PWID in a real-world setting and the factors that affect it. Methods We performed a retrospective analysis of 174 PWID with chronic hepatitis C who started DAAs in a Greek liver clinic in collaboration with an addiction program. Patients who did not return for reassessment were considered as lost to follow up (LTFU). A logistic regression model was used to assess factors associated with a sustained virological response 12 weeks after treatment completion (SVR12) and LTFU. Results Patients' mean age was 48±9.2 years and 91/174 (52.3%) were attending opioid substitution treatment programs. Overall, 144/174 (82.8%) patients completed therapy and presented for SVR12 testing, 8/174 (4.6%) did not complete treatment and 22/174 (12.6%) were LTFU. Overall SVR12 was 79.9% (139/174). For those with an available SVR12 test the response rate reached 96.5% (139/144). Regression analysis did not indicate any significant association between patient characteristics and SVR12. Age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|